Seattle Genetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SGEN Nasdaq 8731 http://www.seattlegenetics.com/ 46.37 Stock Down -0.80

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Seattle Genetics, Inc.

See what the IHS Markit Score report has to say about Seattle Genetics Inc. - Aug 16th, 2017 6:06 am
FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma - Aug 16th, 2017 6:00 am
Edited Transcript of SGEN earnings conference call or presentation 27-Jul-17 8:30pm GMT - Aug 11th, 2017 5:31 pm
IHS Markit Score upgrades Seattle Genetics Inc to 75 out of 100, despite ranking positively in only one IHS Markit category. - Aug 10th, 2017 6:07 am
Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen - Aug 4th, 2017 5:40 am
Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis - Aug 3rd, 2017 5:10 am
Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb - Aug 1st, 2017 2:00 pm
Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing) - Jul 31st, 2017 2:00 pm
ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down - Jul 31st, 2017 1:19 pm
Seattle Genetics (SGEN) Q2 Loss Narrower than Expected - Jul 28th, 2017 9:16 am
Seattle Genetics reports 2Q loss - Jul 27th, 2017 3:58 pm
Seattle Genetics Reports Second Quarter 2017 Financial Results - Jul 27th, 2017 2:02 pm
Investor Network: Seattle Genetics, Inc. to Host Earnings Call - Jul 27th, 2017 8:45 am
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression - Jul 25th, 2017 6:00 am
Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer - Jul 24th, 2017 6:00 am
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals - Jul 14th, 2017 7:30 am
5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates - Jul 13th, 2017 12:31 pm
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017 - Jul 6th, 2017 6:00 am